Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Model: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC). It provides debt and equity growth capital, primarily structured mezzanine debt, to technology-related and life-sciences companies. The company elected to be treated as a Regulated Investment Company (RIC) effective January 1, 2006.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Investment Portfolio (Fair Value) | $283.2 million | $176.7 million |
| Total Investment Income | $29.5 million | $10.7 million |
| Net Investment Income | $10.5 million | $1.3 million |
| Net Realized Gain (Loss) | ($1.6 million) | $0.5 million |
| Net Unrealized Appreciation | $2.5 million | $0.4 million |
| Net Increase in Net Assets from Operations | $11.4 million | $2.1 million |
| Total Assets | $301.1 million | $193.6 million |
| Total Net Assets | $255.4 million | $114.4 million |
| Net Asset Value (NAV) per Share | $11.65 | $11.67 |
| Outstanding Debt | $41.0 million | $76.0 million |
| Unfunded Commitments | $55.5 million | $30.2 million |
| Weighted Average Yield to Maturity | 12.64% | 12.87% |
Material Changes vs. Prior Period
- Portfolio Growth: The investment portfolio grew by approximately 60% (from $176.7 million to $283.2 million) driven by $193.0 million in funded debt investments and $3.0 million in equity investments.
- Revenue Expansion: Total investment income increased 176% to $29.5 million, primarily due to a larger portfolio and higher origination activity. Interest income rose to $26.3 million from $9.8 million.
- Expense Increase: Total operating expenses rose to $18.4 million from $9.1 million. This was driven by higher interest expense ($5.8 million vs. $1.8 million) due to increased leverage, higher compensation costs ($5.8 million vs. $3.7 million), and increased general and administrative expenses related to public company compliance.
- Debt Reduction: The company repaid its $25 million Bridge Loan Credit Facility in full during 2006. Outstanding borrowings under the Citigroup Facility were $41.0 million at year-end, down from $76.0 million in 2005.
- Tax Status: The company transitioned from a C-Corporation to a RIC effective January 1, 2006. Consequently, no provision for federal income taxes was recorded for 2006 operations, whereas a $255,000 expense was recorded in 2005.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to increase investment activity in established companies in 2007. The company anticipates funding investment activities through a combination of debt and additional equity capital. A public offering in late 2006 raised approximately $104.1 million net of costs.
Dividends: The company declared a quarterly dividend of $0.30 per share in 2006. On February 7, 2007, a subsequent dividend of $0.30 per share was announced.
Risks and Contingencies:
- Concentration Risk: The portfolio is concentrated in technology and life sciences. The top 10 portfolio companies represented 43.4% of the total fair value at year-end. Four individual investments exceeded 5% of net assets.
- Valuation Uncertainty: Approximately 94% of total assets are investments in private companies valued at fair value by the Board of Directors, which may differ from values realized upon sale.
- Liquidity and Leverage: The company relies on the Citigroup Facility for liquidity. A warrant participation agreement requires the company to pay Citigroup 10% of realized gains on warrants until a $3.75 million limit is reached.
- Regulatory Compliance: As a BDC, the company must maintain an asset coverage ratio of at least 200% (723% at year-end) to issue senior securities or pay dividends.
Investor Verification Checklist
- Portfolio Quality: Verify the weighted average investment grading of 2.14 and the specific status of the 11 portfolio companies graded 3 or 4 (representing 13.9% of debt portfolio).
- Valuation Methodology: Review the Board's fair value determination process for the 99% of the portfolio lacking readily available market prices.
- Debt Covenants: Confirm compliance with the Citigroup Facility covenants, including the 55% advance rate and industry/geographic concentration limits.
- Warrant Participation: Assess the impact of the Citigroup warrant participation agreement on future realized gains and net asset value.
- Capital Deployment: Monitor the utilization of the $55.5 million in unfunded commitments and the $109.0 million in available borrowing capacity.